Skip to main content
. 2019 Sep 4;18(5):4467–4480. doi: 10.3892/ol.2019.10807

Figure 6.

Figure 6.

Kaplan-Meier survival curves of OS and PRFS based on ex-miR-92a levels in patients with stage II and III GC. (A) Comparison of OS in patients with stage II and III GC with high and low expression levels of ex-miR-92a (n=129). (B) Comparison of PRFS in patients with stage II and III GC with high and low expression levels of ex-miR-92a (n=129). ex-miR-92a, exosome-encapsulated microRNA-92a; GC, gastric cancer; OS, overall survival; PRFS, peritoneal recurrence-free survival.